10-May-2024
Aadi Bioscience GAAP EPS of -$0.68 misses by $0.06, revenue of $5.4M misses by $1.29M
Seeking Alpha News (Wed, 8-May 8:04 AM ET)
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
PRNewswire (Wed, 8-May 8:00 AM ET)
Aadi Bioscience Q1 2024 Earnings Preview
Seeking Alpha News (Tue, 7-May 2:25 PM ET)
Notable earnings before Wednesday's open
Seeking Alpha News (Tue, 7-May 11:00 AM ET)
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
PRNewswire (Wed, 1-May 8:01 AM ET)
PRNewswire (Tue, 9-Apr 8:00 AM ET)
PRNewswire (Sun, 17-Mar 8:00 AM ET)
PRNewswire (Wed, 13-Mar 8:00 AM ET)
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
PRNewswire (Wed, 6-Mar 8:00 AM ET)
PRNewswire (Tue, 5-Mar 4:30 PM ET)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Aadi Bioscience trades on the NASDAQ stock market under the symbol AADI.
As of May 10, 2024, AADI stock price declined to $1.78 with 199,764 million shares trading.
AADI has a beta of -0.32, meaning it tends to be less sensitive to market movements. AADI has a correlation of 0.00 to the broad based SPY ETF.
AADI has a market cap of $43.71 million. This is considered a Sub-Micro Cap stock.
Last quarter Aadi Bioscience reported $5 million in Revenue and -$.68 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.04.
The top ETF exchange traded funds that AADI belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
AADI has underperformed the market in the last year with a price return of -74.9% while the SPY ETF gained +27.8%. AADI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.8% and +1.7%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
AADI support price is $1.79 and resistance is $1.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AADI stock will trade within this expected range on the day.